세계 항체약물접합체(ADC) 시장 규모는 2023년 108억 달러에서 예측 기간 동안 28.4%의 CAGR을 기록하며 2029년에는 470억 달러 규모에 이를 것으로 예상됩니다.
미세관 억제제 부문은 2023년 67억 달러에서 연평균 25.6% 성장하여 2029년에는 257억 달러에 달할 것으로 예상됩니다. DNA 표적화제 부문은 2023년 41억 달러에서 연평균 32.2% 성장하여 2029년에는 211억 달러에 달할 것으로 예측됩니다.
세계 항체약물접합체(ADC) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- ADC 컴포넌트
- 약물 항체비(DAR)
- ADC의 구조
- ADC의 이점
- 접합
- 기존 접합
- 부위 특이적 접합
- 주요 ADC 표적
- 승인된 ADC
제3장 시장 역학
- 시장 역학 현황
- 시장 성장 촉진요인
- 암이환율 상승과 종양학의 미충족 수요
- 리스크 적은 개발
- ADC의 복잡성
- ADC 치료 모달리티에 대한 투자가 신뢰
- 규제 당국에서 지원
- 제한사항
- 기술과 제조 과제
- ADC 저항
제4장 신기술과 개발
- 이중 특이성 또는 이중 표적 ADC
- 이중 페이로드 ADC
- 면역관문억제제와 조합한 ADC
- B7-H3 항체 표적
- 부위 특이적 접합
- 파이프라인 분석
- 페이로드 유형
- 링커 유형
- 항체 종류
- 표시 유형
- 표적 유형
- 접합 종류
- 개발 단계별 신규 ADC
제5장 시장 세분화 분석
- 세분화 내역
- 시장 분석 : 페이로드 유형별
- 시장 개요
- 시장 매출·예측
- 링커 유형별 시장 분석
- 시장 개요
- 시장 매출·예측
- 시장 분석 : 항체 유형별
- 시장 개요
- 시장 매출·예측
- 시장 분석 : 적응증별
- 시장 개요
- 시장 매출·예측
- 지역적 내역
- 시장 분석 : 지역별
- 북미
- 유럽
- 기타 지역
제6장 경쟁 정보
제7장 부록
- 조사 방법
- 정보 출처
- 약어
- 기업 개요
- ABBVIE INC.
- ADC THERAPEUTICS SA
- DAIICHI SANKYO CO. LTD.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- PFIZER INC.
ksm
The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.
The microtubule inhibitors market for antibody-drug conjugates is estimated to increase from $6.7 billion in 2023 to reach $25.7 billion by 2029, at a CAGR of 25.6% from 2024 through 2029.
The DNA targeting agents market for antibody-drug conjugates is estimated to increase from $4.1 billion in 2023 to reach $21.1 billion by 2029, at a CAGR of 32.2% from 2024 through 2029.
Report Scope
This report focuses on the global market for antibody-drug conjugates (ADCs), offering an updated review that covers their fundamental design and use across different oncology fields. In this report, market segmentation is based on payload, linker, antibody, indications, and region. The report also discusses current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations, opportunities, and the latest trends in the ADC market are also discussed in the report.
The report only covers antibody-drug conjugates in which an antibody is conjugated with small-molecule cytotoxic agents (also called payload) through a linker. Alternative antibody conjugates, such as those involving antibodies linked to radioisotopes, are not covered in this report.
Report Includes
- 25 data tables and 45 additional tables
- An updated review of the global market for antibody drug conjugates
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, forecasts for 2025, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for antibody drug conjugates, and corresponding market share analysis by payload type, linker type, antibody type, indication and region
- Coverage of the latest approvals, recalls, safety alerts, and clinical trials; the technical issues related to human anti-mouse antibody (HAMA); and the factors affecting mAB drugs
- Information about major and emerging technologies for the formulation of antibody drug conjugates and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Discussions of the market dynamics, opportunities and challenges
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Daiichi Sankyo, Pfizer Inc., and Gilead Sciences
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Components of ADCs
- Drug-to-antibody Ratio (DAR)
- How ADCs Work
- Advantages of ADCs
- Conjugation Methods
- Conventional Conjugation Method
- Site-Specific Conjugation
- Key ADC Targets
- Approved ADCs
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Rising Prevalence of Cancer and Unmet Need in Oncology
- De-risked Development
- Complexity of ADCs
- Investor Confidence in ADC Therapeutic Modality
- Support from Regulatory Agencies
- Limitations
- Technical and Manufacturing Challenges
- ADC Resistance
Chapter 4 Emerging Technologies and Developments
- Bispecific or Dual-Targeted ADCs
- Dual Payload ADCs
- ADCs in Combination with Immune Checkpoint Inhibitors
- B7-H3 Antibody Target
- Site-specific Conjugation
- Pipeline Analysis
- Payload Type
- Linker Type
- Antibody Type
- Indication Type
- Target Type
- Conjugation Method Type
- Novel ADCs in Development, by Phase
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Payload Type
- Market Overview
- Market Revenue and Forecast
- Market Analysis, by Linker Type
- Market Overview
- Market Revenue and Forecast
- Market Analysis, by Type of Antibody
- Market Overview
- Market Revenue and Forecast
- Market Analysis, by Indication
- Market Overview
- Market Revenue and Forecast
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Other Regions
Chapter 6 Competitive Intelligence
- ADC Sales
- Market Share Analysis
Chapter 7 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBVIE INC.
- ADC THERAPEUTICS SA
- DAIICHI SANKYO CO. LTD.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- PFIZER INC.
